Fulcrum Therapeutics (NASDAQ:FULC) Given "Neutral" Rating at HC Wainwright

HC Wainwright reiterated their neutral rating on shares of Fulcrum Therapeutics (NASDAQ:FULC - Free Report) in a report published on Wednesday,Benzinga reports. The firm currently has a $4.00 price target on the stock. HC Wainwright also issued estimates for Fulcrum Therapeutics' Q1 2025 earnings at ($0.27) EPS, Q2 2025 earnings at ($0.28) EPS, Q3 2025 earnings at ($0.29) EPS, Q4 2025 earnings at ($0.32) EPS, FY2025 earnings at ($1.16) EPS, FY2026 earnings at ($1.36) EPS, FY2027 earnings at ($1.35) EPS, FY2028 earnings at ($1.15) EPS and FY2029 earnings at ($0.95) EPS.

Separately, Royal Bank of Canada restated a "sector perform" rating and set a $4.00 target price on shares of Fulcrum Therapeutics in a research report on Thursday, November 14th. One equities research analyst has rated the stock with a sell rating, six have assigned a hold rating and two have assigned a buy rating to the stock. According to data from MarketBeat.com, Fulcrum Therapeutics currently has a consensus rating of "Hold" and an average target price of $8.63.

Fulcrum Therapeutics Stock Up 6.5 %

Fulcrum Therapeutics stock traded up $0.22 during mid-day trading on Wednesday, hitting $3.59. The company had a trading volume of 368,499 shares, compared to its average volume of 463,136. The stock has a market cap of $193.78 million, a price-to-earnings ratio of -11.58 and a beta of 2.03. Fulcrum Therapeutics has a 1 year low of $2.86 and a 1 year high of $13.70. The business has a fifty day moving average of $4.11 and a 200 day moving average of $4.57.

Remove Ads

Fulcrum Therapeutics (NASDAQ:FULC - Get Free Report) last announced its earnings results on Tuesday, February 25th. The company reported ($0.31) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.28) by ($0.03). Equities analysts anticipate that Fulcrum Therapeutics will post -0.16 earnings per share for the current year.

Institutional Investors Weigh In On Fulcrum Therapeutics

Several hedge funds have recently modified their holdings of FULC. Suvretta Capital Management LLC lifted its holdings in shares of Fulcrum Therapeutics by 182.3% during the fourth quarter. Suvretta Capital Management LLC now owns 3,338,466 shares of the company's stock worth $15,691,000 after purchasing an additional 2,155,675 shares during the period. Braidwell LP acquired a new stake in shares of Fulcrum Therapeutics during the third quarter worth $3,817,000. Adage Capital Partners GP L.L.C. lifted its holdings in shares of Fulcrum Therapeutics by 50.0% during the fourth quarter. Adage Capital Partners GP L.L.C. now owns 3,000,000 shares of the company's stock worth $14,100,000 after purchasing an additional 1,000,000 shares during the period. Woodline Partners LP lifted its holdings in shares of Fulcrum Therapeutics by 110.3% during the fourth quarter. Woodline Partners LP now owns 1,410,520 shares of the company's stock worth $6,629,000 after purchasing an additional 739,713 shares during the period. Finally, State Street Corp lifted its holdings in shares of Fulcrum Therapeutics by 61.4% during the third quarter. State Street Corp now owns 1,680,229 shares of the company's stock worth $5,998,000 after purchasing an additional 638,955 shares during the period. 89.83% of the stock is owned by institutional investors and hedge funds.

About Fulcrum Therapeutics

Fulcrum Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial.